Abstract
Aberrant glycosylation is frequently found in cancer, and efforts for biomarker discovery include the preparation of aberrant glycoproteins as promising analytes. Several lectins that bind to aberrant glycans and can be thus used to capture and enrich aberrant glycoproteins in the frontal stage during biomarker discovery are to be introduced.
Keywords: Aberrant glycosylation, biomarker, cancer, lectin, glycosyltransferase
Protein & Peptide Letters
Title: Implication of Aberrant Glycosylation in Cancer and Use of Lectin for Cancer Biomarker Discovery
Volume: 16 Issue: 5
Author(s): Yong-Sam Kim, Hyang Sook Yoo and Jeong Heon Ko
Affiliation:
Keywords: Aberrant glycosylation, biomarker, cancer, lectin, glycosyltransferase
Abstract: Aberrant glycosylation is frequently found in cancer, and efforts for biomarker discovery include the preparation of aberrant glycoproteins as promising analytes. Several lectins that bind to aberrant glycans and can be thus used to capture and enrich aberrant glycoproteins in the frontal stage during biomarker discovery are to be introduced.
Export Options
About this article
Cite this article as:
Kim Yong-Sam, Yoo Sook Hyang and Ko Heon Jeong, Implication of Aberrant Glycosylation in Cancer and Use of Lectin for Cancer Biomarker Discovery, Protein & Peptide Letters 2009; 16 (5) . https://dx.doi.org/10.2174/092986609788167798
DOI https://dx.doi.org/10.2174/092986609788167798 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Farnesylated Proteins as Anticancer Drug Targets: From Laboratory to the Clinic
Current Medicinal Chemistry - Anti-Cancer Agents Pore-forming Peptides: A New Treatment Option for Cancer
Current Medicinal Chemistry Brain Drug Delivery System: An Overview
Current Drug Therapy Recent Patents on Light Based Therapies: Photodynamic Therapy, Photothermal Therapy and Photoimmunotherapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Recent Advancements in Nanodiamond Mediated Brain Targeted Drug Delivery and Bioimaging of Brain Ailments: A Holistic Review
Pharmaceutical Nanotechnology Viral Vectors for Gene-Directed Enzyme Prodrug Therapy
Current Gene Therapy The Applications of Targeting Anti-Cancer Agents in Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Aquaporins and Glia
Current Neuropharmacology Sphingosine Kinases Signalling in Carcinogenesis
Mini-Reviews in Medicinal Chemistry New Alkyl-Lipid Blockers of SK3 Channels Reduce Cancer Cell Migration and Occurrence of Metastasis
Current Cancer Drug Targets Recent Advances in Receptor-Targeted Fluorescent Probes for In Vivo Cancer Imaging
Current Medicinal Chemistry De Novo DNMTs and DNA Methylation: Novel Insights into Disease Pathogenesis and Therapy from Epigenomics
Current Pharmaceutical Design Perspectives of Protein Kinase C (PKC) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Genomic Context Vectors and Artificial Chromosomes for Cystic Fibrosis Gene Therapy
Current Gene Therapy Brain Permeable Nanoparticles
Recent Patents on CNS Drug Discovery (Discontinued) Design and Synthesis of Novel Thiosemicarbazones as Potent Anti-breast Cancer Agents
Letters in Drug Design & Discovery Fibroblast Growth Factor-Inducible 14: Multiple Roles in Tumor Metastasis
Current Molecular Medicine Indole Compounds Against Breast Cancer: Recent Developments
Current Drug Targets Cyclooxygenases in the Central Nervous System: Implications for Treatment of Neurological Disorders
Current Pharmaceutical Design Molecular Targets of FTY720 (Fingolimod)
Current Molecular Medicine